Nkarta to Participate in an Upcoming Investor Conference
Rhea-AI Summary
Nkarta (Nasdaq: NKTX), a biopharmaceutical company focused on engineered natural killer (NK) cell therapies, has announced its upcoming participation in the 7th Annual Evercore HealthCONx Conference. The company will participate in a fireside chat scheduled for December 4, 2024, at 2:10 p.m. ET.
The event will be accessible through a live webcast on Nkarta's website investor section, with a replay available for approximately 90 days following the presentation.
Positive
- None.
Negative
- None.
News Market Reaction – NKTX
On the day this news was published, NKTX gained 0.77%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
SOUTH SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference:
7th Annual Evercore HealthCONx Conference
December 4, 2024
2:10 p.m. ET – fireside chat
A simultaneous webcast of the event will be available on the Investors section of Nkarta’s website, www.nkartatx.com, and a replay will be archived on the website for approximately 90 days.
About Nkarta
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep therapeutic activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company’s website at www.nkartatx.com.
Nkarta Media/Investor Contact:
Greg Mann
Nkarta, Inc.
gmann@nkartatx.com